These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10516368)

  • 1. Optimizing the use of parenteral iron in end-stage renal disease patients: focus on issues of infection and cardiovascular disease. Introduction.
    Owen WF
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S1-2. PubMed ID: 10516368
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
    Hood SA; O'Brien M; Higgins R
    Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of parenteral iron dextran therapy.
    Burns DL; Pomposelli JJ
    Kidney Int Suppl; 1999 Mar; 69():S119-24. PubMed ID: 10084295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining iron balance with total-dose infusion of intravenous iron dextran.
    Case G
    ANNA J; 1998 Feb; 25(1):65-8. PubMed ID: 9543911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Parenteral iron replacement].
    Cynke E
    Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
    [No Abstract]   [Full Text] [Related]  

  • 8. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron administration in a short-stay hospital setting.
    Peebles G; Fenwick S
    Nurs Stand; 2008 Aug 6-12; 22(48):35-41. PubMed ID: 18727354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
    Dahdah K; Patrie JT; Bolton WK
    Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 16. Stability of iron dextran (DexFerrum) in peritoneal dialysis bags.
    Manley HJ; Grabe DW; Bailie GR; Norcross ML
    Perit Dial Int; 1998; 18(5):538-40. PubMed ID: 9848638
    [No Abstract]   [Full Text] [Related]  

  • 17. Parenteral iron dextran therapy: a review.
    Burns DL; Mascioli EA; Bistrian BR
    Nutrition; 1995; 11(2):163-8. PubMed ID: 7647482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does iron cause bacterial infections in patients with end stage renal disease?
    Cieri E
    ANNA J; 1999 Dec; 26(6):591-6. PubMed ID: 10876474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe intravascular haemolysis and acute renal failure following intravenous administration of iron dextran.
    Buus NH; Jensen JD
    Nephrol Dial Transplant; 2007 Feb; 22(2):661-2. PubMed ID: 16968716
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
    Bhandari S; Naudeer S
    J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.